Exhibit 99.1

AutoImmune Inc.

1199 Madia Street

Pasadena, CA 91103

Phone: 626-792-1235

Fax: 626-792-1236

Contact:

Robert C. Bishop, Ph.D.

Chairman and Chief Executive Officer

AutoImmune Inc.

626-792-1235

website: http://www.autoimmuneinc.com

FOR IMMEDIATE RELEASE

AUTOIMMUNE INC. REPORTS 2009 SECOND QUARTER FINANCIAL RESULTS

Pasadena, California, August 6, 2009 - AutoImmune Inc. (OTC BB: AIMM.OB) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008. For the six months ended June 30, 2009, the net loss was $256,000, or $0.02 per share basic and diluted, compared with net loss of $193,000, or $0.01 per share basic and diluted for the same period in 2008. As of June 30, 2009, the Company reported $8.2 million in cash and marketable securities as compared to $8.5 million in cash and marketable securities as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, “Product sales in the first six months of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., more than doubled from the same period in 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging.” AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R “Consolidation of Variable Interest Entities.”

AutoImmune has exclusively licensed certain of its intellectual property rights pertaining to an injectable therapy for the treatment of multiple sclerosis to BioMS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of all products covered by the license agreement. BioMS Medical Corp. and Eli Lilly and Company recently reported that dirucotide, the lead drug covered by AutoImmune’s license agreement with BioMS, did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Eli Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data. Chairman of the Board and Chief Executive Officer Robert C. Bishop,

Ph.D. stated, “We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS.”

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune’s dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled “Risk Factors.” We have no plans, and disclaim any obligation, to update or revise any forward-looking statements whether as a result of new information, future events or other factors, except as required by law.

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)


	Three months ended June 30,						Six months ended June 30,
	2008			2009			2008			2009
Revenue	$	101,000		$	184,000		$	168,000		$	288,000


Costs and expenses:
Cost of goods sold		16,000			50,000			28,000			70,000
Research and development		48,000			30,000			90,000			101,000
General and administrative		181,000			180,000			386,000			368,000

Total costs and expenses		245,000			260,000			504,000			539,000


Interest income		60,000			8,000			144,000			17,000

		60,000			8,000			144,000			17,000


Net loss		(84,000	)		(68,000	)		(192,000	)		(234,000	)
Net income (loss) attributable to noncontrolling interest		2,000			18,000			1,000			22,000


Net loss attributable to AutoImmune Inc	$	(86,000	)	$	(86,000	)	$	(193,000	)	$	(256,000	)


Net loss per share - basic	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.02	)


Net loss per share - diluted	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.02	)


Weighted average common shares outstanding - basic		16,999,623			16,999,623			16,998,414			16,999,623


Weighted average common shares outstanding - diluted		16,999,623			16,999,623			16,998,414			16,999,623

CONDENSED BALANCE SHEET

(Unaudited)


	December 31, 2008		June 30, 2009
Cash and short-term marketable securities	$	8,475,000	$	6,927,000
Other current assets		195,000		232,000
Long-term marketable securities		—		1,302,000


Total assets	$	8,670,000	$	8,461,000


Current liabilities	$	147,000	$	122,000
Total equity		8,523,000		8,339,000


Total liabilities and equity	$	8,670,000	$	8,461,000

AUTOIMMUNE INC 8-K